Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

Caplin, Martyn E

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. [electronic resource] - Endocrine-related cancer Mar 2016 - 191-9 p. digital

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1479-6821

10.1530/ERC-15-0490 doi


Antineoplastic Agents--adverse effects
Disease-Free Survival
Humans
Intestinal Neoplasms--drug therapy
Neuroendocrine Tumors--drug therapy
Pancreatic Neoplasms--drug therapy
Peptides, Cyclic--adverse effects
Somatostatin--adverse effects
Treatment Outcome